A study evaluating effect of Emricasan (IDN-6556) on levels of MP-encapsu- lated cCK-18 and active caspase-3/7 in subjects with chronic liver diseases.
Phase of Trial: Phase II
Latest Information Update: 18 Jan 2017
At a glance
- Drugs Emricasan (Primary)
- Indications Liver injury
- Focus Pharmacodynamics; Therapeutic Use
- 18 Jan 2017 New trial record